Organogenesis Holdings Inc (NASDAQ:ORGO) — Market Cap & Net Worth
Market Cap & Net Worth: Organogenesis Holdings Inc (ORGO)
Organogenesis Holdings Inc (NASDAQ:ORGO) has a market capitalization of $304.59 Million ($304.59 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14865 globally and #3461 in its home market, demonstrating a 0.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Organogenesis Holdings Inc's stock price $2.40 by its total outstanding shares 126912142 (126.91 Million). Review Organogenesis Holdings Inc (ORGO) total liabilities to assess the company's total debt and financial obligations.
Organogenesis Holdings Inc Market Cap History: 2017 to 2026
Organogenesis Holdings Inc's market capitalization history from 2017 to 2026. Data shows change from $1.26 Billion to $304.59 Million (-13.79% CAGR).
Index Memberships
Organogenesis Holdings Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.01% | #400 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1442 of 3165 |
Weight: Organogenesis Holdings Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Organogenesis Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Organogenesis Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.84x
Organogenesis Holdings Inc's market cap is 0.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
471.68x
Organogenesis Holdings Inc's market cap is 471.68 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.29 Billion | $193.45 Million | -$64.83 Million | 6.66x | N/A |
| 2019 | $610.45 Million | $260.98 Million | -$38.71 Million | 2.34x | N/A |
| 2020 | $955.65 Million | $338.30 Million | $17.23 Million | 2.82x | 55.45x |
| 2021 | $1.17 Billion | $467.36 Million | $94.20 Million | 2.51x | 12.45x |
| 2022 | $341.39 Million | $450.89 Million | $15.53 Million | 0.76x | 21.98x |
| 2023 | $519.07 Million | $433.14 Million | $4.95 Million | 1.20x | 104.97x |
| 2024 | $406.12 Million | $482.04 Million | $861.00K | 0.84x | 471.68x |
Competitor Companies of ORGO by Market Capitalization
Companies near Organogenesis Holdings Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Organogenesis Holdings Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Organogenesis Holdings Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Organogenesis Holdings Inc's market cap moved from $1.26 Billion to $ 304.59 Million, with a yearly change of -13.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $304.59 Million | -53.67% |
| 2025 | $657.40 Million | +61.88% |
| 2024 | $406.12 Million | -21.76% |
| 2023 | $519.07 Million | +52.04% |
| 2022 | $341.39 Million | -70.89% |
| 2021 | $1.17 Billion | +22.71% |
| 2020 | $955.65 Million | +56.55% |
| 2019 | $610.45 Million | -52.61% |
| 2018 | $1.29 Billion | +2.32% |
| 2017 | $1.26 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Organogenesis Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $304.59 Million USD |
| MoneyControl | $304.59 Million USD |
| MarketWatch | $304.59 Million USD |
| marketcap.company | $304.59 Million USD |
| Reuters | $304.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barrier… Read more